Which Antipsoriatic Drug Has the Fastest Onset of Action?—Systematic Review on the Rapidity of the Onset of Action
- 1 August 2013
- journal article
- review article
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 133 (8) , 1963-1970
Abstract
No abstract availableKeywords
Funding Information
- Novartis
- Abbott Laboratories
- Pfizer
This publication has 59 references indexed in Scilit:
- A randomized, double‐blind, placebo‐controlled study to evaluate the addition of methotrexate to etanercept in patients with moderate to severe plaque psoriasisBritish Journal of Dermatology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Definition of treatment goals for moderate to severe psoriasis: a European consensusArchives of Dermatological Research, 2010
- Comparison of Ustekinumab and Etanercept for Moderate-to-Severe PsoriasisNew England Journal of Medicine, 2010
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)The Lancet, 2008
- Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)The Lancet, 2008
- Psoriasis Area and Severity Index 50 as an endpoint in psoriasis trials: An unconvincing proposalJournal of the American Academy of Dermatology, 2005
- An extended 16-week course of alefacept in the treatment of chronic plaque psoriasisJournal of the American Academy of Dermatology, 2005
- A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasisJournal of the American Academy of Dermatology, 2004
- Low-dose short-term cyclosporine versus etretinate in psoriasis: Improvement of skin, nail, and joint involvementJournal of the American Academy of Dermatology, 1995